<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">689930</article-id><article-id pub-id-type="doi">10.17816/dv689930</article-id><article-id pub-id-type="edn">RFMMSN</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Potential for effective treatment and prevention of periungual fibromas and angiofibromas in tuberous sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности эффективного лечения и профилактики околоногтевых фибром и ангиофибром при туберозном склерозе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8485-3294</contrib-id><contrib-id contrib-id-type="spin">5216-2059</contrib-id><name-alternatives><name xml:lang="en"><surname>Gaydina</surname><given-names>Tatiana A.</given-names></name><name xml:lang="ru"><surname>Гайдина</surname><given-names>Татьяна Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>doc429@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2239-7235</contrib-id><contrib-id contrib-id-type="spin">4105-3517</contrib-id><name-alternatives><name xml:lang="en"><surname>Sharova</surname><given-names>Natalia M.</given-names></name><name xml:lang="ru"><surname>Шарова</surname><given-names>Наталья Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>nataliasharova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0429-3117</contrib-id><contrib-id contrib-id-type="spin">2023-5783</contrib-id><name-alternatives><name xml:lang="en"><surname>Dvornikov</surname><given-names>Anton S.</given-names></name><name xml:lang="ru"><surname>Дворников</surname><given-names>Антон Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>dvornikov_as@rsmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2639-6811</contrib-id><contrib-id contrib-id-type="spin">3711-3460</contrib-id><name-alternatives><name xml:lang="en"><surname>Kukalo</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>Кукало</surname><given-names>Светлана Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>svetlana_kukalo@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0312-4853</contrib-id><contrib-id contrib-id-type="spin">5004-0378</contrib-id><name-alternatives><name xml:lang="en"><surname>Silin</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>Силин</surname><given-names>Алексей Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>silin_aa@rsmu.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-6852-1531</contrib-id><contrib-id contrib-id-type="spin">6559-5647</contrib-id><name-alternatives><name xml:lang="en"><surname>Ponkratova</surname><given-names>Lyudmila Р.</given-names></name><name xml:lang="ru"><surname>Понкратова</surname><given-names>Людмила Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Ponkratova_lp@rsmu.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Center of Brain Research and Neurotechnologies</institution></aff><aff><institution xml:lang="ru">Федеральный центр мозга и нейротехнологий</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-26" publication-format="electronic"><day>26</day><month>12</month><year>2025</year></pub-date><volume>28</volume><issue>6</issue><issue-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</issue-title><issue-title xml:lang="ru">Российский журнал кожных и венерических болезней</issue-title><fpage>643</fpage><lpage>656</lpage><history><date date-type="received" iso-8601-date="2025-08-27"><day>27</day><month>08</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-11-15"><day>15</day><month>11</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-12-26"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/689930">https://rjsvd.com/1560-9588/article/view/689930</self-uri><abstract xml:lang="en"><p>Tuberous sclerosis is an orphan neurocutaneous hereditary disorder characterized by multisystem involvement and age-dependent manifestation of symptoms. The disease results from sporadic or inherited mutations in TSC1 (9q34, hamartin) or TSC2 (16p13.3, tuberin). Under normal conditions, TSC1 and TSC2 regulate cell proliferation and tumor growth by inhibiting the mTORC1 complex (mechanistic target of rapamycin complex 1). Mutations in TSC1 and TSC2 disrupt formation of the hamartin–tuberin complex, leading to persistent activation of mTORC1 and uncontrolled cellular proliferation.</p> <p>A detailed description of cutaneous manifestations of tuberous sclerosis is crucial for early diagnosis. Angiofibromas and periungual fibromas are major diagnostic criteria for tuberous sclerosis. Although not life-threatening, these tumors significantly impair patients’ quality of life due to their size, bleeding upon trauma, and risk of secondary infection. Removal of angiofibromas and periungual fibromas substantially improves patients’ quality of life. Various removal techniques have been described in the scientific data, with laser modalities offering practical advantages over surgical excision.</p> <p>We followed two adult patients with large facial angiofibromas and periungual fibromas. Angiofibromas and periungual fibromas were removed using a CO<sub>2</sub> laser under local infiltration anesthesia, followed by wound resurfacing with the same device in pulsed mode. Laser output ranged from 2 to 4 W. Immediately after excision, facial angiofibromas were additionally treated intralesionally with a pulsed dye laser. Excised tissue was submitted for histopathologic examination. Outcomes were assessed at 1 month, and patients were subsequently monitored every 3 months for 2 years by a dermatovenereologist. No tumor recurrences were observed during follow-up, underscoring the practical value of this approach for effective fibroma removal and improved quality of life.</p></abstract><trans-abstract xml:lang="ru"><p>Туберозный склероз относится к орфанным нейрокожным наследственным заболеваниям с возможным мультисистемным поражением организма и возрастными особенностями манифестации симптомов. Заболевание обусловлено спорадическими или наследственными мутациями в генах <italic>TSC1</italic> (9q34, гамартин) или <italic>TSC2</italic> (16p13.3, туберин). Гены <italic>TSC1</italic> и <italic>TSC2</italic> в норме регулируют пролиферацию клеток и опухолевый рост путём инактивации комплекса mTORС1 (механистическая мишень рапамицинового комплекса 1). Мутации в генах <italic>TSC1</italic> и <italic>TSC2</italic> блокируют образование белкового комплекса гамартин-туберин, что приводит к постоянной активации mTORС1 и клеточной пролиферации.</p> <p>Подробное описание кожных проявлений туберозного склероза имеет важное практическое значение для ранней диагностики заболевания. Ангио- и околоногтевые фибромы относят к большим критериям диагностики туберозного склероза, при этом они не являются жизнеугрожающими опухолями, однако значительно ухудшают качество жизни пациентов вследствие большого размера, кровоточивости при травматизации, присоединения вторичной инфекции. Удаление ангио- и околоногтевых фибром значительно улучшает качество жизни пациентов. В научной литературе описан ряд методов удаления данных образований, при этом лазерные методы имеют определённые практические преимущества перед хирургическим иссечением.</p> <p>Под нашим наблюдением находились двое взрослых пациентов с крупными ангиофибромами кожи лица и околоногтевыми фибромами. Удаление ангиофибром кожи лица и околоногтевых фибром выполняли СО<sub>2</sub>-лазером под местной инфильтрационной анестезией с последующей обработкой раны тем же аппаратом в импульсно-периодическом режиме. Мощность излучения лазера варьировала в диапазоне от 2 до 4 Вт. Ангиофибромы кожи лица сразу после удаления дополнительно внутриочагово обрабатывали PDL-лазером. Удалённый материал направляли на гистологическое исследование. Результаты процедуры оценивали через 1 месяц, далее пациенты находились под динамическим наблюдением, включающим консультации врача-дерматовенеролога каждые 3 месяца в течение 2 лет. На протяжении периода наблюдения у пациентов не было рецидивов опухолей, что имеет важное практическое значение для выбора метода удаления фибром и улучшения качества жизни пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>tuberous sclerosis</kwd><kwd>TSC1</kwd><kwd>TSC2</kwd><kwd>hamartoma</kwd><kwd>periungual fibromas</kwd><kwd>angiofibromas</kwd><kwd>case report</kwd><kwd>CO2 laser</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>туберозный склероз</kwd><kwd>TSC1</kwd><kwd>TSC2</kwd><kwd>гамартома</kwd><kwd>околоногтевые фибромы</kwd><kwd>ангиофибромы</kwd><kwd>клинический случай</kwd><kwd>СО2-лазер</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Northrup H, Aronow ME, Bebin EM, et al.; International Tuberous Sclerosis Complex Consensus Group. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50–66. doi: 10.1016/j.pediatrneurol.2021.07.011 EDN: ILZBRU</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kwiatkovski DJ, Whittemore VH, Thiele EA. Tuberous sclerosis complex: genes, clinical features and therapeutics. USA, Wiley-Blackwell; 2010. 432 р. ISBN 978-3-527-63007-3</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Varenova TN, Goshadze VA, Akutina DI, Pomerantsev ON. Long-term undiagnosed tuberous sclerosis. Vestnik dermatologii i venerologii. 2021;97(3):66–72. doi: 10.25208/vdv1237 EDN: CGRITJ</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gómez MR. History of the tuberous sclerosis complex. Brain Dev. 1995;17Suppl:55–57. doi: 10.1016/0387-7604(94)00130-8</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–254. doi: 10.1016/j.pediatrneurol.2013.08.001</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wataya-Kaneda M, Uemura M, Fujita K, et al. Tuberous sclerosis complex: recent advances in manifestations and therapy. Int J Urol. 2017;24(9):681–691. doi: 10.1111/iju.13390 EDN: YGLIDX</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Keln AA, Semenova EV, Keln OL, Shvedskyi MS. Tuberous sclerosis with kidneys angiomyolipomas: a family case. Urology Herald. 2023;11(1):165–170. doi: 10.21886/2308-6424-2023-11-1-165-170 EDN: WCBBOH</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hong CH, Tu HP, Lin JR, Lee CH. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997–2010). Br J Dermatol. 2016;174(6):1282–1289. doi: 10.1111/bjd.14415</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kishida S, Nakatani E, Usui T, et al. Epidemiological insights and healthcare challenges of tuberous sclerosis complex in Shizuoka Prefecture: a retrospective cohort study. Orphanet J Rare Dis. 2025;20(1):245. doi: 10.1186/s13023-025-03799-w</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Belaya SA, Likhachev SA, Kulikova SL, et al. A lesion of the nervous system associated with tsc in childhood. Own observations. Neurology and neurosurgery. Eastern Europe. 2021;11(4):465–480 doi: 10.34883/PI.2021.11.4.048 EDN: RUYKJQ</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Troitskaya LA, Malakhova NE, Dorofeeva MY. Features of development of higher mental functions in children with tuberous sclerosis. Russian bulletin of perinatology and pediatrics. 2017;62:(4):99–104. doi: 10.21508/1027-4065-2017-62-4-99-104 EDN: ZFCZGL</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80. doi: 10.1086/316951</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dufner Almeida LG, Nanhoe S, Zonta A, et al. Comparison of the functional and structural characteristics of rare TSC2 variants with clinical and genetic findings. Hum Mutat. 2020;41(4):759–773. doi: 10.1002/humu.23963</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Duan J, Pan S, Ye Y, et al. Uncovering hidden genetic variations: long-read sequencing reveals new insights into tuberous sclerosis complex. Front Cell Dev Biol. 2024;12:1423244. doi: 10.3389/fcell.2024.1415258 EDN: ZCEFWU</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Curatolo P, Moavero R, Roberto D, Graziola F. Genotype/phenotype correlations in tuberous sclerosis complex. Semin Pediatr Neurol. 2015;22(4):259–273. doi: 10.1016/j.spen.2015.10.002 EDN: WRWXKF</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kwiatkowski DJ, Palmer MR, Jozwiak S, et al. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur J Hum Gen. 2015;23(12):1665–1672. doi: 10.1038/ejhg.2015.47 EDN: VELENL</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976. doi: 10.1016/j.cell.2017.02.004</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Altunina GE, Balayan IG, Belousova ED, et al. Tuberous sclerosis. Diagnostics and treatment. Dorofeeva MYu, editor. Moscow: Adare; 2017. 288 р. (In Russ.) EDN: XQAKKT</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lepesova MM, Isabekova AA, Kuderbayeva DA, Orazaliev BA. Features of clinical manifestations, diagnosis, and treatment of tuberous sclerosis in children. Actual problems of theoretical and clinical medicine. 2024;(2):57–66. doi: 10.24412/2790-1289-2024-2-57-66 EDN: ZPFTSF</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dorofeeva MYu, Belousova ED, Pivovarova AM. Recommendations for diagnosis and treatment of tuberous sclerosis. S.S. Korsakov J Neurol Psych. 2014;114(3):58–74. EDN: SDIJGZ</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Okanishi T, Fujimori I, Yamada M, et al. Diagnostic flow analysis of tuberous sclerosis complex in Japan: a retrospective claims database study. Orphanet J Rare Dis. 2024;19(1):451. doi: 10.1186/s13023-024-03460-y EDN: VDQZAS</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gaydina TA, Dvornikov AS, Skripkina PA, Arutyunyan GB. Rationale for removing nevus sebaceus of Jadassohn in young patients. Bull Russ State Med University. 2018;(3):77–80. doi: 10.24075/brsmu.2018.033 EDN: YAWSPB</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Gaydina TA, Dvornikov AS, Skripkina PA, et al. Differential diagnosis of Brooke–Spiegler syndrome in a young woman with multiple trichoepitheliomas. Russ J Skin Venereal Dis. 2022;25(6):5–16. doi: 10.17816/dv112260 EDN: WUIKXO</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lodi G, Cannarozzo G, Fusco I, et al. Effective technique using combined CO2 laser and pulsed dye laserfor facial angiofibromas management in tuberous sclerosis. Case Rep Dermatol Med. 2024;2024:9775613. doi: 10.1155/2024/9775613 EDN: ICKPLY</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Neamonitou F, Neamonitos KK, Stavrianos S, Neamonitos KP. A triple laser combination treatment for facial angiofibromata management in tuberous sclerosis and literature review. Arch Plast Surg. 2024;51(4):372–377. doi: 10.1055/a-2306-0962 EDN: VDOTLP</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons,reduced myelination, seizure activity, and limited survival. J Neurosci. 2007;27(21):5546–5558. doi: 10.1523/JNEUROSCI.5540-06.20074</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin preventsepilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63(4):444–453. doi: 10.1002/ana.213315</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ehninger D, Silva AJ. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med. 2011;17(2):78–87. doi: 10.1016/j.molmed.2010.10.002 EDN: OARDPF</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Morozov SL, Piruzieva OR, Dlin VV. Effectiveness of targeted therapy for kidney damage with tuberous sclerosis in a child (clinical case). Nephrology. 2021;25(4):90–94. doi: 10.36485/1561-6274-2021-25-4-90-94 EDN: JGHKXT</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kologrivko EV, Rucina KA, Akhidzhak AN. Tuberosis sclerosis during pregnancy and inuterine at the fetus. Nauchnyi vestnik zdravookhraneniya Kubani. 2023;(3):29–42. EDN: SPHLBM</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Nunes BA, Romano AK, Pasa Morgan MA, et al. A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC). An Bras Dermatol. 2024;99(5):662–669. doi: 10.1016/j.abd.2023.11.004 EDN: JFRBDV</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Deng S, Shi W, Cai Y, et al. Tuberous sclerosis complex with skin lesions as the initial presentation: a case report and multidisciplinary discussion. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47(7):973–980. doi: 10.11817/j.issn.1672-7347.2022.210452</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Li Y, Wang Z, Yang Y, Xu X. Tuberous sclerosis complex presenting as periungual fibromas: a rare case report and literature review. Clin Cosmet Investig Dermatol. 2024;17:2747–2753. doi: 10.2147/CCID.S488272 EDN: ZCLCWG</mixed-citation></ref></ref-list></back></article>
